Screening of biomarkers for prediction of multisite artery disease in patients with recent myocardial infarction

References

• Calais F, Eriksson Ostman M, Hedberg P, et al. Incremental prognostic value of coronary and systemic atherosclerosis after myocardial infarction. Int J Cardiol. 2018;261:6–11.
   PubMed Web of Science ®Google Scholar
• Jonelid B, Johnston N, Berglund L, et al. Ankle brachial index most important to identify polyvascular disease in patients with non-ST elevation or ST-elevation myocardial infarction. Eur J Intern Med. 2016;30:55–60.
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Eagle KA, Kline-Rogers E, et al. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol. 2007;100(1):1–6.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Cimminiello C, Meneghetti G, et al. Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events. J Thromb Haemost. 2006;4:2599–2606.
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197–1206.
   PubMed Web of Science ®Google Scholar
• Berger JS, Abramson BL, Lopes RD, et al. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: insights from the EUCLID trial. Vasc Med. 2018;23:523–530.
   PubMed Web of Science ®Google Scholar
• Poredos P, Poredos P, Jezovnik MK. Structure of atherosclerotic plaques in different vascular territories: clinical relevance. Curr Vasc Pharmacol. 2018;16:125–129.
   PubMed Web of Science ®Google Scholar
• Khawaja FJ, Kullo IJ. Novel markers of peripheral arterial disease. Vasc Med. 2009;14:381–392.
   PubMed Web of Science ®Google Scholar
• Grenon SM, Vittinghoff E, Owens CD, et al. Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: insights from the heart and soul study. Vasc Med. 2013;18:176–184.
   PubMed Web of Science ®Google Scholar
• Rein P, Saely CH, Silbernagel G, et al. Systemic inflammation is higher in peripheral artery disease than in stable coronary artery disease. Atherosclerosis. 2015;239(2):299–303.
   PubMed Web of Science ®Google Scholar
• Bob-Manuel T, Ifedili I, Reed G, et al. Non-ST elevation acute coronary syndromes: a comprehensive review. Curr Probl Cardiol. 2017;42:266–305.
   PubMed Web of Science ®Google Scholar
• Christersson C, Lindahl B, Berglund L, et al. The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients. Ups J Med Sci. 2017;122(4):224–233.
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551–2567.
   PubMed Web of Science ®Google Scholar
• Schroder F, Diehm N, Kareem S, et al. A modified calculation of ankle-brachial pressure index is far more sensitive in the detection of peripheral arterial disease. J Vasc Surg. 2006;44(3):531–536.
   PubMed Web of Science ®Google Scholar
• Lind L, Arnlov J, Lindahl B, et al. Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. Atherosclerosis. 2015;242:205–210.
   PubMed Web of Science ®Google Scholar
• Santema BT, Kloosterman M, Van Gelder IC, et al. Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. Eur Heart J. 2018;39(43):3867–3875.
   PubMed Web of Science ®Google Scholar
• Kulasingam A, Hvas AM, Grove EL, et al. Detection of biomarkers using a novel proximity extension assay in patients with ST-elevation myocardial infarction. Thromb Res. 2018;172:21–28.
   PubMed Web of Science ®Google Scholar
• Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLOS One. 2014;9(4):e95192.
   PubMed Web of Science ®Google Scholar
• Lundberg M, Eriksson A, Tran B, et al. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res. 2011;39:e102.
   PubMed Web of Science ®Google Scholar
• White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30:377–399.
   PubMed Web of Science ®Google Scholar
• Westfall PH, Young SS. Resampling-based multiple testing: examples and methods for p-value adjustment. United States: John Wiley and Sons; 1993.
   Google Scholar
• Breiman L. Random forests. Mach Learn. 2001;45(1):5–32.
   Web of Science ®Google Scholar
• Hoefer IE, den Adel B, Daemen MJ. Biomechanical factors as triggers of vascular growth. Cardiovasc Res. 2013;99:276–283.
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874.
   PubMed Web of Science ®Google Scholar
• Kottoor SJ, Arora RR. The utility of anti-inflammatory agents in cardiovascular disease: a novel perspective on the treatment of atherosclerosis. J Cardiovasc Pharmacol Ther. 2018;23:483–493.
   PubMed Web of Science ®Google Scholar
• Dutta P, Courties G, Wei Y, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;487:325–329.
   PubMed Web of Science ®Google Scholar
• Cooke JP, Wilson AM. Biomarkers of peripheral arterial disease. J Am Coll Cardiol. 2010; 55:2017–2023.
   PubMed Web of Science ®Google Scholar
• Fanola CL, Morrow DA, Cannon CP, et al. Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: observations from the SOLID-TIMI 52 (stabilization of plaque using darapladib-thrombolysis in myocardial infarction 52). Trial J Am Heart Assoc. 2017;6(10):e005637
   Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–1695.
   PubMed Web of Science ®Google Scholar
• Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC study group. Fragmin during instability in coronary artery disease. N Engl J Med. 2000;343:1139–1147.
   PubMed Web of Science ®Google Scholar
• Parameswaran N, Patial S. Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010;20:87–103.
   PubMed Web of Science ®Google Scholar
• Nash M, McGrath JP, Cartland SP, et al. Tumour necrosis factor superfamily members in ischaemic vascular diseases. Cardiovasc Res. 2019;115:713–720.
   PubMed Web of Science ®Google Scholar
• Mehta AK, Gracias DT, Croft M. TNF activity and T cells. Cytokine. 2018;101:14–18.
   PubMed Web of Science ®Google Scholar
• Han KH, Hennigar RA, O’Neill WC. The association of bone and osteoclasts with vascular calcification. Vasc Med. 2015;20:527–533.
   PubMed Web of Science ®Google Scholar
• Kaptoge S, Seshasai SR, Gao P, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35:578–589.
   PubMed Web of Science ®Google Scholar
• Safranow K, Dziedziejko V, Rzeuski R, et al. Plasma concentrations of TNF-alpha and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease. Tissue Antigens. 2009;74:386–392.
   PubMedGoogle Scholar
• Aboyans V, Criqui MH, Abraham P, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012;126:2890–2909.
   PubMed Web of Science ®Google Scholar
• Desmedt S, Desmedt V, De VL, et al. Growth differentiation factor 15: a novel biomarker with high clinical potential. Crit Rev Clin Lab Sci. 2019;;56(5):333–350.
   PubMed Web of Science ®Google Scholar
• Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem. 2017;63:140–151.
   PubMed Web of Science ®Google Scholar
• Kempf T, Bjorklund E, Olofsson S, et al. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007;28(23):2858–2865.
   PubMed Web of Science ®Google Scholar
• Hsu LA, Wu S, Juang JJ, et al. Growth differentiation factor 15 may predict mortality of peripheral and coronary artery diseases and correlate with their risk factors. Mediators Inflamm. 2017;2017:1–13.
   Web of Science ®Google Scholar
• De Haan JJ, Haitjema S, den Ruijter HM, et al. Growth differentiation factor 15 is associated with major amputation and mortality in patients with peripheral artery disease. J Am Heart Assoc. 2017;6:1–10.
   Web of Science ®Google Scholar
• Farhan S, Freynhofer MK, Brozovic I, et al. Determinants of growth differentiation factor 15 in patients with stable and acute coronary artery disease. A prospective observational study. Cardiovasc Diabetol. 2016;15(1):60.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Zethelius B, Berglund L, et al. GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. PLOS One. 2013;8(12):e78797.
   PubMed Web of Science ®Google Scholar
• Skau E, Henriksen E, Wagner P, et al. GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction. Eur J Prev Cardiol. 2017;24:1576–1583.
   PubMed Web of Science ®Google Scholar